Biotech | November 18, 2021
AstraZeneca’s Covid-19 drug offers 83% protection over six months
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Evidence also shows better immune response to virus among users of spray
Filing marks first protein-based vaccine submitted to MHRA for authorization
Key takeaways of recent quarter & conference call highlights
Second interchangeable biosimilar product approved by agency
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Subscribe To Our Newsletter & Stay Updated
